Business
Swiss online pharmacy DocMorris 2025 revenue meets growth targets
Swiss online pharmacy DocMorris 2025 revenue meets growth targets
About this update from Docmorris Ltd
OverviewSwiss online pharmacy's 2025 external revenue grew 11.1%, achieving growth targets2025 revenue increased by as much as 12.4% to CHF 1.12 billion, achieving growth targetsDigital services, including TeleClinic, saw significant growth in 2025Q4 external revenue rose 15.5%, driven by increased marketing efficiency for prescription medicinesOutlookDocMorris confirms EBITDA breakeven in 2026 and free cash flow breakeven in 2027Company specifies 2025 EBITDA forecast to a range of minus CHF 48 to minus CHF 52 millionResult DriversDIGITAL SERVICES GROWTH - TeleClinic revenue increased by 124% in 2025, highlighting its strategic importance in the German marketAI ASSISTANT USAGE - Introduction of AI health assistant saw usage by every third app user, enhancing digital platform expansionQ4 REVENUE ACCELERATION - Q4 external revenue rose 15.5%, driven by increased marketing efficiency for prescription medicinesKey DetailsMetricFY External RevenueBeat/MissActualCHF 1.19 blnConsensus EstimateAnalyst CoverageThe current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"The average consensus recommendation for the drug retailers peer group is "buy."Wall Street's median 12-month price target for DocMorris AG is CHF8.10, about 25.5% above its January 19 closing price of CHF6.46Press Release: For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .